Is Bristol-Myers Squibb Stock Underperforming the S&P 500?

Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products. With a market cap of $98.7 billion, the company focuses on products and experimental therapies that address cancer, heart disease, HIV and AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection, and psychiatric disorders.

Companies worth $10 billion or more are generally described as “large-cap stocks.” BMY effortlessly fits that bill, with its market cap exceeding this mark, underscoring its size, influence, and dominance within the general drug manufacturing industry. BMY's commitment to innovation is evident in its dynamic drug pipeline, and its focus on immuno-oncology has resulted in a suite of pioneering treatments that have become standard care in various cancers. This innovation-driven approach not only solidifies BMY's brand but also ensures a steady stream of revenue through patented drugs, contributing to its competitive advantage.